Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat. Some preclinical work, largely based on cell lines, suggested KRAS(mut) lung cancers are especially dependent on the nuclear export protein ex...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Rosen, Joshua C., Weiss, Jessica, Pham, Nhu-An, Li, Quan, Martins-Filho, Sebastiao N., Wang, Yuhui, Tsao, Ming-Sound, Moghal, Nadeem
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8313753/
https://ncbi.nlm.nih.gov/pubmed/34284202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101179
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars